Carbon nitride-based nanocaptor: An intelligent nanosystem with metal ions chelating eﬀect for enhanced magnetic targeting phototherapy of Alzheimer's disease

Gong, Li; Zhang, Xing; Ge, Kezhen; Yin, Yiming; Machuki, Jeremiah Ong’achwa; Yang, Yun; Shi, Hengliang; Geng, Deqin; Gao, Fenglei

doi:10.1016/j.biomaterials.2020.120483

Cited by 44 publications

(32 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The imbalance of metal ions leads to the accumulation of amyloid-β peptide (Aβ) proteins, causing neurological diseases such as Alzheimer’s and Parkinson’s [ 36 ]. There are many studies in the literature to prevent Aβ aggregation by chelating Cu(II) and Fe(II) ions [ 37 ]. In the process of leading to iron overload-related diseases, metallic iron creates highly toxic Reactive Oxygen Species (ROS) [ 38 ].…”

Section: Resultsmentioning

confidence: 99%

Chondroitin Sulfate-Based Cryogels for Biomedical Applications

Demirci

Şahiner

Ari

et al. 2021

Gels

View full text Add to dashboard Cite

Cryogels attained from natural materials offer exceptional properties in applications such as tissue engineering. Moreover, Halloysite Nanotubes (HNT) at 1:0.5 weight ratio were embedded into CS cryogels to render additional biomedical properties. The hemolysis index of CS cryogel and CS:HNT cryogels was calculated as 0.77 ± 0.41 and 0.81 ± 0.24 and defined as non-hemolytic materials. However, the blood coagulation indices of CS cryogel and CS:HNT cryogels were determined as 76 ± 2% and 68 ± 3%, suggesting a mild blood clotting capability. The maximum% swelling capacity of CS cryogel was measured as 3587 ± 186%, 4014 ± 184%, and 3984 ± 113%, at pH 1.0, pH 7.4 and pH 9.0, respectively, which were reduced to 1961 ± 288%, 2816 ± 192, 2405 ± 73%, respectively, for CS:HNT cryogel. It was found that CS cryogels can hydrolytically be degraded 41 ± 1% (by wt) in 16-day incubation, whereas the CS:HNT cryogels degraded by 30 ± 1 wt %. There is no chelation for HNT and 67.5 ± 1% Cu(II) chelation for linear CS was measured. On the other hand, the CS cryogel and CS:HNT cryogel revealed Cu(II) chelating capabilities of 60.1 ± 12.5%, and 43.2 ± 17.5%, respectively, from 0.1 mg/mL Cu(II) ion stock solution. Additionally, at 0.5 mg/mL CS, CS:HNT, and HNT, the Fe(II) chelation capacity of 99.7 ± 0.6, 86.2 ± 4.7% and only 11.9 ± 4.5% were measured, respectively, while no Fe(II) was chelated by linear CS chelated Fe(II). As the adjustable and controllable swelling properties of cryogels are important parameters in biomedical applications, the swelling properties of CS cryogels, at different solution pHs, e.g., at the solution pHs of 1.0, 7.4 and 9.0, were measured as 3587 ± 186%, 4014 ± 184%, and 3984 ± 113%, respectively, and the maximum selling% values of CS:HNT cryogels were determined as 1961 ± 288%, 2816 ± 192, 2405 ± 73%, respectively, at the same conditions. Alpha glucosidase enzyme interactions were investigated and found that CS-based cryogels can stimulate this enzyme at any CS formulation.

show abstract

Section: Resultsmentioning

confidence: 99%

Chondroitin Sulfate-Based Cryogels for Biomedical Applications

Demirci

Şahiner

Ari

et al. 2021

Gels

View full text Add to dashboard Cite

show abstract

“…(3) In addition to Aβ aggregation, other pathological factors in AD pathogenesis can also be targeted or modulated by multipronged agents. These factors include elevated oxidative stress, abnormally hyperphosphorylated tau proteins, irreversible neuron loss, and copper accumulation. − Multifunctional platforms with both therapeutic modalities and modalities that incorporate BBB translocation, stimuli-responsive drug release, multitarget direction, real-time diagnostics, and in situ imaging are indispensable in diminishing the off-target adverse reactions and in the evaluation of therapeutic effects. − Therefore, the inhibition of tau hyperphosphorylation using PDT or PTT will also be a potential therapeutic direction for AD.…”

Section: Discussionmentioning

confidence: 99%

Photothermal and Photodynamic Therapies via NIR-Activated Nanoagents in Combating Alzheimer’s Disease

Zeng

Peng

Han

et al. 2021

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

It is well established that the polymerization of amyloid-β peptides into fibrils/plaques is a critical step during the development of Alzheimer’s disease (AD). Phototherapy, which includes photodynamic therapy and photothermal therapy, is a highly attractive strategy in AD treatment due to its merits of operational flexibility, noninvasiveness, and high spatiotemporal resolution. Distinct from traditional chemotherapies or immunotherapies, phototherapies capitalize on the interaction between photosensitizers or photothermal transduction agents and light to trigger photochemical reactions to generate either reactive oxygen species or heat effects to modulate Aβ aggregation, ultimately restoring nerve damage and ameliorating memory deficits. In this Review, we provide an overview of the recent advances in the development of near-infrared-activated nanoagents for AD phototherapies and discuss the potential challenges of and perspectives on this emerging field with a special focus on how to improve the efficiency and utility of such treatment. We hope that this Review will spur preclinical research and the clinical translation of AD treatment through phototherapy.

show abstract

“…(b) Schematic illustration of the B-FeCN nanosystem as a multifunctional nanocaptor to inhibit Aβ aggregation for the magnetic targeting phototherapy of AD treatment. Reprinted with permission from reference [ 159 ]. Copyright 2021 Elsevier.…”

Section: Figures and Schemementioning

confidence: 99%

“…In addition, BTA endowed the nanocaptor with aspecific targeting ability and fluorescent imaging property for monitoring Aβ aggregates. choring C3N4 nanodots to Fe3O4@MSNs and modifying them with benzothiazole aniline (BTA) (B-FeCN), as shown in Figure 12C [159]. In this nanocomposite, C3N4 nanodots could capture Cu 2+ , subsequently blocking the formation of the Aβ-Cu 2+ complex and diminishing Aβ aggregation.…”

Section: Graphitic Carbon Nitridementioning

confidence: 99%

Nanomaterials for Modulating the Aggregation of β-Amyloid Peptides

et al. 2021

View full text Add to dashboard Cite

The aberrant aggregation of amyloid-β (Aβ) peptides in the brain has been recognized as the major hallmark of Alzheimer’s disease (AD). Thus, the inhibition and dissociation of Aβ aggregation are believed to be effective therapeutic strategiesforthe prevention and treatment of AD. When integrated with traditional agents and biomolecules, nanomaterials can overcome their intrinsic shortcomings and boost their efficiency via synergistic effects. This article provides an overview of recent efforts to utilize nanomaterials with superior properties to propose effective platforms for AD treatment. The underlying mechanismsthat are involved in modulating Aβ aggregation are discussed. The summary of nanomaterials-based modulation of Aβ aggregation may help researchers to understand the critical roles in therapeutic agents and provide new insight into the exploration of more promising anti-amyloid agents and tactics in AD theranostics.

show abstract

Carbon nitride-based nanocaptor: An intelligent nanosystem with metal ions chelating eﬀect for enhanced magnetic targeting phototherapy of Alzheimer's disease

Cited by 44 publications

References 55 publications

Chondroitin Sulfate-Based Cryogels for Biomedical Applications

Chondroitin Sulfate-Based Cryogels for Biomedical Applications

Photothermal and Photodynamic Therapies via NIR-Activated Nanoagents in Combating Alzheimer’s Disease

Nanomaterials for Modulating the Aggregation of β-Amyloid Peptides

Contact Info

Product

Resources

About